QuantumPharm, Inc. (HK:2228)
:2228
Top Page
QuantumPharm, Inc.
(2228)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$8.50
▼(-18.66% Downside)
Action:ReiteratedDate:03/26/26
The score is primarily held back by weak underlying fundamentals (ongoing operating losses and sustained cash burn) despite improved scale and a stronger balance sheet. Technicals also indicate a prevailing downtrend, and valuation looks demanding given the high P/E and lack of dividend support.
Positive Factors
Balance Sheet Improvement
The material increase in equity versus modest debt materially reduces near-term refinancing and solvency risk. A stronger capital base improves runway against cash burn, increasing the company's ability to invest in growth and absorb shocks without immediate external funding.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow means the business is not self-funding and remains dependent on external capital. Continued cash burn raises dilution and refinancing risk and constrains reinvestment capacity if sustained beyond the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Improvement
The material increase in equity versus modest debt materially reduces near-term refinancing and solvency risk. A stronger capital base improves runway against cash burn, increasing the company's ability to invest in growth and absorb shocks without immediate external funding.
Read all positive factors
QuantumPharm, Inc. (2228) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$41.29B
Dividend YieldN/A
Average Volume (3M)143.30M
Price to Earnings (P/E)266.6
Beta (1Y)0.92
Revenue Growth243.78%
EPS Growth97.15%
CountryHK
Employees809
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.01
Shares Outstanding4,303,371,600
10 Day Avg. Volume160,836,692
30 Day Avg. Volume143,301,077
Financial Highlights & Ratios
PEG Ratio-2.56
Price to Book (P/B)3.42
Price to Sales (P/S)41.11
P/FCF Ratio-160.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$15.00Price Target Upside43.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$913.80M
QuantumPharm, Inc. Business Overview & Revenue Model
Company Description
XtalPi Holdings Limited, an investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan. The company's drug discovery solutions cover the whole drug discovery...
QuantumPharm, Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 781.85M | 266.43M | 174.42M | 133.35M | 62.80M |
| Gross Profit | 544.71M | 123.43M | 48.24M | 66.09M | 32.78M |
| EBITDA | -383.89M | -631.38M | -1.78B | -1.38B | -2.11B |
| Net Income | 120.54M | -1.52B | -1.91B | -1.44B | -2.14B |
Balance Sheet | |||||
| Total Assets | 10.22B | 4.35B | 4.01B | 4.32B | 4.38B |
| Cash, Cash Equivalents and Short-Term Investments | 7.07B | 3.10B | 2.83B | 3.47B | 3.83B |
| Total Debt | 443.46M | 148.76M | 11.04B | 9.45B | 7.83B |
| Total Liabilities | 786.95M | 362.43M | 11.25B | 9.63B | 7.99B |
| Stockholders Equity | 9.39B | 3.96B | -7.27B | -5.33B | -3.61B |
Cash Flow | |||||
| Free Cash Flow | -199.96M | -536.79M | -698.20M | -627.83M | -417.42M |
| Operating Cash Flow | -139.62M | -478.68M | -567.56M | -429.10M | -253.75M |
| Investing Cash Flow | -3.87B | 74.09M | 735.58M | -2.76B | -70.47M |
| Financing Cash Flow | 5.43B | 840.00M | -25.89M | 57.99M | 2.48B |
QuantumPharm, Inc. Technical Analysis
Neutral
10.45
Price Trends
10.67
Negative
10.60
Negative
9.76
Negative
Market Momentum
-0.31
Negative
47.05
Neutral
61.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2228, the sentiment is Neutral. The current price of 10.45 is above the 20-day moving average (MA) of 9.58, below the 50-day MA of 10.67, and above the 200-day MA of 9.76, indicating a neutral trend. The MACD of -0.31 indicates Negative momentum. The RSI at 47.05 is Neutral, neither overbought nor oversold. The STOCH value of 61.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2228.
QuantumPharm, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$76.93B | 46.00 | 19.62% | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$811.10M | -11.05 | -3.55% | ― | 2.76% | -293.57% | |
48 Neutral | HK$15.87B | -106.74 | -11.44% | ― | ― | ― | |
46 Neutral | HK$1.66B | -5.33 | -39.41% | ― | ― | 47.42% | |
46 Neutral | HK$4.51B | -54.41 | -48.44% | ― | ― | ― | |
42 Neutral | HK$41.29B | 266.61 | 1.50% | ― | 243.78% | 97.15% |
* General Sector Average
HK:2228
QuantumPharm, Inc.
9.60
5.63
141.81%
HK:2268
WuXi XDC Cayman, Inc.
61.15
31.35
105.20%
HK:2502
Henan Jinyuan Hydrogenated Chemicals Co., Ltd. Class H
0.49
0.20
67.24%
HK:2511
Hightide Therapeutics Inc
3.26
2.02
162.90%
HK:2498
RoboSense Technology Company., Ltd
33.22
5.37
19.28%
HK:2509
Qyuns Therapeutics Co., Ltd. Class H
19.88
11.98
151.65%
QuantumPharm, Inc. Corporate Events
XtalPi Swings to Profit on Surging 2025 Revenue and Heavy R&D Spend
Mar 25, 2026
XtalPi Holdings Limited reported a sharp increase in revenue to RMB802.6 million for the year ended 31 December 2025, up from RMB266.4 million a year earlier, reflecting strong business expansion. The company remained RD-intensive, with research a...
XtalPi Sets March 25 Board Meeting to Approve 2025 Annual Results
Mar 13, 2026
XtalPi Holdings Limited has scheduled a board meeting for 25 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025 and to authorize their publication. The board will also consider the payme...
XtalPi Names Veteran Healthcare Banker Zhou Feiran as Chief Financial Officer
Mar 10, 2026
XtalPi Holdings Limited has appointed Zhou Feiran as its new chief financial officer, effective 10 March 2026, strengthening its senior leadership team with a seasoned capital markets specialist. Zhou brings over 12 years of experience in global h...
XtalPi Signals First Full-Year Profit on Revenue Surge and Valuation Gains
Mar 3, 2026
XtalPi Holdings has issued a positive profit alert, signaling a turnaround from a net loss of about RMB1.5 billion in 2024 to an expected net profit of at least RMB100 million in 2025, marking its first full-year profit. The shift is driven by a p...
XtalPi Expands AI-Driven Lab Automation With BASF Workstation Deployment
Feb 9, 2026
XtalPi has strengthened its position in automated chemistry by successfully deploying an advanced automated formulation stability testing workstation for BASF, a major global chemical producer. The system integrates sample management, analytical t...
XtalPi Completes HK$2.87 Billion Zero-Coupon Convertible Bond Issue to Fund AI-Driven R&D Expansion
Jan 28, 2026
XtalPi Holdings Limited has completed the issuance of HK$2.866 billion zero-coupon convertible bonds due 2027, following satisfaction of all conditions under its subscription agreement, with listing and trading of the bonds on the Hong Kong Stock ...
XtalPi to Raise HK$2.87 Billion via Zero-Coupon Convertible Bonds for Global Expansion
Jan 7, 2026
XtalPi Holdings Limited has agreed to issue HK$2.866 billion in zero-coupon convertible bonds due 2027, following a book-building exercise that set an initial conversion price of HK$13.85 per share. On full conversion, the bonds would translate in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.